Nemaura Medical to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
Nemaura Medical (NASDAQ: NMRD) announced CEO Dr. Faz Chowdhury will present at the MicroCap Rodeo Windy City Roundup 2022 Conference, taking place from October 12-13, 2022 at the Swissotel Chicago. His presentation is scheduled for 1:00 pm CT on October 12. Dr. Chowdhury will also hold one-on-one meetings with investors registered for the event. Nemaura specializes in non-invasive glucose monitoring technology, including products like sugarBEAT and proBEAT, addressing the growing market for diabetes management.
- None.
- None.
Loughborough, England, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at at the MicroCap Rodeo Windy City Roundup 2022 Conference. The conference is being held on October 12 – 13, 2022 at the Swissotel Chicago.
Presentation Date: October 12, 2022
Time: 1:00 pm CT
Dr. Chowdhury will be available for one-on-one meetings with investors who are registered to attend the conference. To schedule a meeting, please email angie.wright@issuerdirect.com
To register for the conference, click here: https://microcaprodeo.com/signup
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.
Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly
For more information, please visit www.NemauraMedical.com.
Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
FAQ
What is the date and time of Nemaura Medical's presentation at the MicroCap Rodeo Conference?
Where is the MicroCap Rodeo Windy City Roundup 2022 Conference being held?
Who is presenting for Nemaura Medical at the conference?
What products does Nemaura Medical focus on?
What is the significance of Nemaura Medical’s products in the diabetes market?
